Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment

Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients

(2011) Kazuma Kiyotani et al.   BREAST CANCER RESEARCH AND TREATMENT

Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score

(2011) M F Barginear et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

(2011) T E Mürdter et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

(2011) L Madlensky et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment

(2011) Anne-Joy M. de Graan et al.   JOURNAL OF CLINICAL ONCOLOGY

Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor–Positive Breast Cancer

(2011) Chungyeul Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

(2011) William J. Irvin et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment

(2011) Wendy Lorizio et al.   Genome Medicine

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

(2010) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor   for Degradation in Breast Cancer Cells

(2009) X. Wu et al.   CANCER RESEARCH

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

(2009) Werner Schroth   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

(2009) J M Rae et al.   PHARMACOGENOMICS JOURNAL